Tags

Type your tag names separated by a space and hit enter

The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
Scand J Clin Lab Invest. 1975 May; 35(3):205-10.SJ

Abstract

The growth-hormone-release-inhibiting hormone somatostatin was infused in seven juvenile diabetic subjects during an arginine infusion test and in six juvenile diabetic subjects during an L-dopa stimulation test. The plasma growth hormone response to arginine and L-dopa was completely inhibited by somatostatin. The plasma pancreatic glucagon response to arginine was also inhibited by somatostatin. The plasma pancreatic glucagon level was not changed by L-dopa, but somatostatin induced a significant fall in this level. The plasma glucose increase after arginine and L-dopa administration was slightly inhibited by somatostatin. The arginine-induced fall in free fatty acids was prevented by somatostatin, and the L-dopa-induced rise in free fatty acids was enhanced by somatostatin. The growth hormone- and glucagon-surppressive effect of somatostatin may prove useful in controlling the metabolic state and in preventing the development of angiopathy in diabetic patients. A somatostatin preparation with prolonged activity is needed for lifelong administration, but the presently available compound may be of value as an adjunct in the standard treatment of diabetic ketoacidosis and coma.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

1153917

Citation

Hansen, A P., et al. "The Effect of Somatostatin On the Rise of Growth Hormone and Glucagon Secretion Induced By Arginine and L-dopa in Diabetic Patients." Scandinavian Journal of Clinical and Laboratory Investigation, vol. 35, no. 3, 1975, pp. 205-10.
Hansen AP, Christensen SE, Lundbaek K. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients. Scand J Clin Lab Invest. 1975;35(3):205-10.
Hansen, A. P., Christensen, S. E., & Lundbaek, K. (1975). The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients. Scandinavian Journal of Clinical and Laboratory Investigation, 35(3), 205-10.
Hansen AP, Christensen SE, Lundbaek K. The Effect of Somatostatin On the Rise of Growth Hormone and Glucagon Secretion Induced By Arginine and L-dopa in Diabetic Patients. Scand J Clin Lab Invest. 1975;35(3):205-10. PubMed PMID: 1153917.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients. AU - Hansen,A P, AU - Christensen,S E, AU - Lundbaek,K, PY - 1975/5/1/pubmed PY - 1975/5/1/medline PY - 1975/5/1/entrez SP - 205 EP - 10 JF - Scandinavian journal of clinical and laboratory investigation JO - Scand J Clin Lab Invest VL - 35 IS - 3 N2 - The growth-hormone-release-inhibiting hormone somatostatin was infused in seven juvenile diabetic subjects during an arginine infusion test and in six juvenile diabetic subjects during an L-dopa stimulation test. The plasma growth hormone response to arginine and L-dopa was completely inhibited by somatostatin. The plasma pancreatic glucagon response to arginine was also inhibited by somatostatin. The plasma pancreatic glucagon level was not changed by L-dopa, but somatostatin induced a significant fall in this level. The plasma glucose increase after arginine and L-dopa administration was slightly inhibited by somatostatin. The arginine-induced fall in free fatty acids was prevented by somatostatin, and the L-dopa-induced rise in free fatty acids was enhanced by somatostatin. The growth hormone- and glucagon-surppressive effect of somatostatin may prove useful in controlling the metabolic state and in preventing the development of angiopathy in diabetic patients. A somatostatin preparation with prolonged activity is needed for lifelong administration, but the presently available compound may be of value as an adjunct in the standard treatment of diabetic ketoacidosis and coma. SN - 0036-5513 UR - https://www.unboundmedicine.com/medline/citation/1153917/The_effect_of_somatostatin_on_the_rise_of_growth_hormone_and_glucagon_secretion_induced_by_arginine_and_L_dopa_in_diabetic_patients_ DB - PRIME DP - Unbound Medicine ER -